Shin Yazawa1, Takehiko Yokobori2, Kyoichi Kaira3, Hiroyuki Kuwano2, Takayuki Asao4. 1. Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Japan; Big Data Center for Integrative Analysis, Gunma University Initiative for Advance Research, Maebashi, Japan. Electronic address: syazawa@gunma-u.ac.jp. 2. Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Japan. 3. Department of Oncology Clinical Development, Gunma University Graduate School of Medicine, Maebashi, Japan. 4. Big Data Center for Integrative Analysis, Gunma University Initiative for Advance Research, Maebashi, Japan.
Abstract
BACKGROUND: Upon initiation and progression of cancer, α1-acid glycoprotein (AGP) possessing highly sialylated and fucosylated glycans appears in the serum, and recently has attracted a great deal of attention, as a potential biomarker of tumorigenesis in humans. METHODS: To establish a rapid and precise method for the quantitative assay of fucosylated AGP in serum samples, we developed an enzyme immunoassay (EIA) bearing an anti-AGP antibody and a fucose-binding lectin, Aleuria aurantia (AAL) with additional endeavor to improved sample handling, and antibody preparations. RESULTS: The amounts of fucosylated AGP could be determined by the present method with a good performance feature in all tested samples from both cancer patients and healthy controls. From cancer patients under chemotherapy we show that fucosylated AGP could be a clinically relevant biomarker for cancer progression or prognosis as well as for an early assessment of clinical response and treatment outcomes. Furthermore, in a different setting, fucosylated AGP also showed relevance in patients who received immunotherapy with an anti-programmed cell death-1 (PD-1) antibody. CONCLUSIONS: α1,3fucosylated AGP is a potential biomarker of cancer initiation, progression and response to treatment in cancer patients.
BACKGROUND: Upon initiation and progression of cancer, α1-acid glycoprotein (AGP) possessing highly sialylated and fucosylated glycans appears in the serum, and recently has attracted a great deal of attention, as a potential biomarker of tumorigenesis in humans. METHODS: To establish a rapid and precise method for the quantitative assay of fucosylated AGP in serum samples, we developed an enzyme immunoassay (EIA) bearing an anti-AGP antibody and a fucose-binding lectin, Aleuria aurantia (AAL) with additional endeavor to improved sample handling, and antibody preparations. RESULTS: The amounts of fucosylated AGP could be determined by the present method with a good performance feature in all tested samples from both cancerpatients and healthy controls. From cancerpatients under chemotherapy we show that fucosylated AGP could be a clinically relevant biomarker for cancer progression or prognosis as well as for an early assessment of clinical response and treatment outcomes. Furthermore, in a different setting, fucosylated AGP also showed relevance in patients who received immunotherapy with an anti-programmed cell death-1 (PD-1) antibody. CONCLUSIONS: α1,3fucosylated AGP is a potential biomarker of cancer initiation, progression and response to treatment in cancerpatients.